Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04340843 · ClinicalTrials.gov registry record · Phase 2
Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
A Phase 2 study of Metastatic Primary Central Chondrosarcoma and Unresectable Primary Central Chondrosarcoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 20
- Study locations
NCT04340843 is a Phase 2 study of Metastatic Primary Central Chondrosarcoma and Unresectable Primary Central Chondrosarcoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 19 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT04340843, a Phase 2 study of Metastatic Primary Central Chondrosarcoma and Unresectable Primary Central Chondrosarcoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies the effect of belinostat and SGI-110 (guadecitabine) or ASTX727 in treating patients with conventional chondrosarcoma that cannot be removed by surgery (unresectable) and has spread from where it first started (primary site) to other places in the body (metastatic). Belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as guadecitabine and ASTX727, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving belinostat in combination with guadecitabine or ASTX727 may lower the chance of unresectable and metastatic chondrosarcoma growing or spreading.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Biopsy Procedure
- DRUG Decitabine and Cedazuridine
- DRUG Belinostat
Study Locations (20)
Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables - Coral Gables
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach - Deerfield Beach
- Mayo Clinic in Florida - Jacksonville
- University of Miami Miller School of Medicine-Sylvester Cancer Center - Miami
- UM Sylvester Comprehensive Cancer Center at Plantation - Plantation
- Moffitt Cancer Center - Tampa
Kansas
- HaysMed - Hays
- University of Kansas Cancer Center - Kansas City
- Lawrence Memorial Hospital - Lawrence
- University of Kansas Cancer Center-Overland Park - Overland Park
- Mercy Hospital Pittsburg - Pittsburg
- Salina Regional Health Center - Salina
California
- City of Hope Comprehensive Cancer Center - Duarte
- Los Angeles General Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- USC Norris Oncology/Hematology-Newport Beach - Newport Beach
Arizona
- Mayo Clinic Hospital in Arizona - Phoenix
Colorado
- UCHealth University of Colorado Hospital - Aurora
Connecticut
- Yale University - New Haven
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2020-09-08 |
| Est. Completion | 2027-01-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04340843
The ClinicalTrials.gov registry entry for NCT04340843 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Primary Central Chondrosarcoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT04340843 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, Kansas, California.
Frequently Asked Questions
What is clinical trial NCT04340843 about?
NCT04340843 is a clinical study titled "Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma". This phase II trial studies the effect of belinostat and SGI-110 (guadecitabine) or ASTX727 in treating patients with conventional chondrosarcoma that cannot be removed by surgery (unresectable) and has spread from where it first started (primary site) to other places in the body (metastatic). Belin...
What is the current status of trial NCT04340843?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2020-09-08. Estimated completion is 2027-01-27.
What conditions does trial NCT04340843 study?
This clinical trial studies the following conditions: Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma, Locally Advanced Unresectable Primary Central Chondrosarcoma.
What interventions are being tested in trial NCT04340843?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy Procedure (PROCEDURE), Decitabine and Cedazuridine (DRUG), Belinostat (DRUG).
Who is sponsoring clinical trial NCT04340843?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04340843 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Primary Central Chondrosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Metastatic Primary Central Chondrosarcoma
All registered trials for this condition
Unresectable Primary Central Chondrosarcoma
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.